anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To investigate the effectiveness of anatomical locking plate in the treatment of Rockwood type Ⅰ-Ⅲ patella fractures.
METHODS: The clinical data of 16 patients with patella fractures who were admitted between November 2021 and January 2023 and met the selection criteria was retrospectively analyzed. There were 14 males and 2 females, with an average age of 44.5 years (range, 19-72 years). Causes of injuries included tumble in 12 cases and traffic accident in 4 cases. The fractures were rated as type Ⅰ in 2 cases, type Ⅱ in 9 cases, and type Ⅲ in 5 cases according to Rockwood classification criteria. The time from injury to operation ranged from 6 to 15 days, with an average of 9 days. After fracture reduction, an appropriate anatomical locking plate was selected for internal fixation. The operation time, intraoperative blood loss, and incision healing were recorded; the Lysholm score, Böstman patella fracture efficacy score, knee joint mobility, and visual analogue scale (VAS) score were used to evaluate the knee joint function and pain degree; X-ray films were used to review the fracture reduction and healing.
RESULTS: The operation time was 65-100 minutes (mean, 75.3 minutes); the intraoperative blood loss was 10-35 mL (mean, 25.6 mL). All incisions healed by first intention after operation. All patients were followed up 11-26 months (mean, 19.7 months). X-ray films showed that the fractures were reduced satisfactorily, and all achieved bony healing with healing time of 3-5 months. At last follow-up, the Lysholm score was 90-95 (mean, 93.0); the Böstman patella fracture efficacy score was 27-30 (mean, 28.8), of which 12 cases were excellent and 4 were good; the VAS score was 0-1 (mean, 0.3). There was no significant difference in the range of motion of the knee joint between the healthy and affected sides [145° (140°, 150°) vs 145° (140°, 145°); Z=1.890, P=0.059].
CONCLUSION: Choosing anatomical locking plates for Rockwood typeⅠ-Ⅲ patella fractures can achieve strong fixation with minimal surgical trauma, rapid recovery of knee joint function, and mild pain after operation.
The present disclosure provides a method for assessing drug-resistant microorganism including following steps. A testing sample is provided. A sample pre-processing step is performed so as to obtain a processed sample. An analysis step is performed, wherein the processed sample is processed by a mass spectrometry method so as to a target mass spectrum data. A spectrum pre-processing step is performed to obtain a standardized target mass spectrum data. A feature extraction step is performed so as to obtain a spectrum feature value. An assessing step is performed, wherein the spectrum feature value is trained to achieve a convergence by a drug-resistance assessing classifier so as to output a drug-resistant microorganism assessing result. Therefore, the time required for microbial cultivation and identification as well as the antibiotic susceptibility testing thereof can be greatly shorten, so that the method for assessing drug-resistant microorganism of the present disclosure has application potential in related markets.
Compositions for therapeutic or diagnostic use in connection with bacterial infections containing as an active constituent the structural element, preferably in terminal position: (FORMULA) A process for the therapeutic treatment of mammals including man, comprising administering to the mammal an active amount of such a composition. A process for identification or quantification of such structural element in native biological material from mammals including man, comprising using antibodies, the generation of which has been initiated by such composition. A process for the identification of bacterial acceptor structures (pili, syn. fimbriae) recognizing the described structural element, comprising using such compositions. A process for purifying acceptor structures of bacteria, comprising using for the purification the affinity between such structural element and the corresponding acceptor structures on the bacteria. A method of diagnosing mammals including man in regard to proneness to bacterial infection involving such receptor structure, comprising generating antibodies against said receptor structure and recording the reaction of said antibodies and cells from the mammal.
An attachment component for attaching a tracker of a surgical navigation system to a surgical instrument is disclosed. The attachment component comprises a body and an instrument interface attached to the body and configured for detachable attachment of the attachment component in a predefined position and orientation to a surgical instrument or implant. A tracker interface is attached to the body and has a fixed pre-defined shape for engagement with the tracker interface of the tracker. The instrument interface is arranged in an un-calibrated position relative the tracker interface. A navigation system comprises a tracker with a tracker interface for attachment to the attachment component. The tracker is configured to report position and orientation of its tracker interface. A method implements translation of position and orientation of the tracker into position and orientation of an instrument.
OBJECTIVES: In this study, we examined whether epilepsy and drug-resistant epilepsy are associated with neuroimaging findings in children with cerebral palsy (CP).
METHODS: Magnetic resonance imaging classification system (MRICS) proposed by Surveillance of Cerebral Palsy in Europe (SCPE) was used for classification of different MRI patterns in patients with cerebral palsy. We reviewed the brain MRI scans and medical records of children with CP who were followed-up in our clinic between 2019 and 2023. Patients were divided into three categories: CP without epilepsy, CP with controlled epilepsy and CP with DRE. MRI patterns were grouped as maldevelopments, predominant white matter injury, predominant gray matter injury, miscellaneous (delayed myelination, cerebral atrophy, cerebellar atrophy, brainstem lesions and calcifications, lesions that were not classified under any other group) and normal according to MRICS of the SCPE.
RESULTS: There were 325 CP patients. The most common MRI patterns were predominant white matter injury (47.6%) and gray matter injury (23.8%). There was a 1.5-fold reduction in the risk of epilepsy in patients with predominant white matter injury (OR = 1.54, 95% CI 1.23-1.94). In contrast, children in the miscellaneous group had significantly higher risks of epilepsy (p < 0.001), and we were able to determine that miscellaneous findings increased the risk by 1.8 times (OR = 1.77, 95% CI 1.47-2.12).
CONCLUSION: In conclusion, more than half of the children with CP had epilepsy, 40.7% of whom had DRE. On MRI, miscellaneous findings may indicate a poor prognosis for epilepsy, while predominant white matter injury may indicate a good outcome. Children with CP, especially those with miscellaneous findings on MRI, should be closely monitored for epilepsy development.
Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis. In ASPIRE, the incidence of hypertension events was 17% in the KRd arm versus 9% in the Rd arm. In ENDEAVOR, the incidence of hypertension events was 34% in the Kd arm versus 11% in the Vd arm. In CANDOR, the incidence of hypertension events was 31% in the DKd arm versus 28% in the Kd arm. Some of these events have been fatal.

Optimize blood pressure prior to starting Kyprolis. Monitor blood pressure regularly in all patients while on Kyprolis. If hypertension cannot be adequately controlled, withhold Kyprolis and evaluate. Consider whether to restart Kyprolis based on a benefit/risk assessment.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.

Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.

Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.

Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.

Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely - to pulmonology. The invention contains two versions of implementing the method. Both versions involve introduction of dry powdered aerosol preparation tobramicine into the patient's endobronchial system. In the first version, one dose contains 90 to 130 mg of tobramicine or its pharmaceutically acceptable salt. At the first therapeutic stage, one dose is administered one to three times a day. Duration of the first therapeutic stage is 20 to 36 days. In the second version one dose contains 110 to 115 mg of tobramicine. At the first therapeutic stage, this therapeutic dose is administered twice a day. The first therapeutic stage lasts for 28 days. The therapeutic stage is followed by the second non-therapeutic stage. The non-therapeutic stage lasts for 26 to 30 days. At this stage no antibiotics are introduced into the patient's endobronchial system. Then the first and second therapeutic stages are performed again. ^ EFFECT: method provides required pharmacological effect by administering a smaller dose of dry powder tobramicine in a relatively short time in treating Pseudomonas infections in the patients suffering from cystic fibrosis. ^ 24 cl, 11 tbl, 4 dwg
Drinkable suspension of ibuprofen having a liquid phase in which is suspended solid ibuprofen, the amount of solubilized ibuprofen being less than 10 % by weight of the total ibuprofen present, especially less than 1 %.  The suspension may be prepared from a powdered form and then reconstituted to a liquid, or it may be prepared as a ready-to-use liquid. The ibuprofen particles may be crystalline or granular, optionally coated, the size of the crystals being below 500 mu m. Granules of ibuprofen, which preferably have a particle size of 50 - 1000  mu m, are preferably coated with a polymer to mask the flavor or to ensure modified liberation. The compositions also contain a viscosity agent, preferably a carbomer, Carbopol 917P (RTM) being especially preferred. This preferably constitutes 0.1 - 10 %, especially 0.1 - 1 % of the suspension. Suspensions are aqueous, or a contain a mixture of water and a miscible co-solvent, and may also contain preservatives, sweeteners, pH modifiers, and flavorings.
Bipolar disorder (BD) and Schizophrenia (SZ) are leading causes of disability and are the costliest disorders to treat among serious mental illnesses. Ample evidence exists that evidence-based psychotherapies such as cognitive behavioral therapy (CBT) produce clinically significant improvements in symptoms of BD and SZ, and yet only 5% of patients in the community can access these treatments. Access to CBT for serious mental illnesses is limited by the restricted pool of trained providers, the resource intensity of these treatments, and cessation of reimbursement for psychological services in many public mental health systems. Our research in BD and SZ over the past five years indicates that mobile phones can provide automated yet personalized cognitive behavioral intervention that is feasible, acceptable, and associated with improvements in symptoms, medication adherence and socialization. Our intervention, called CBT2go, integrates ecological momentary assessment with personalized interventions delivered in the moment that symptoms and related experiences occur. We have developed an innovative platform that functions on various screen types, operating system, or data access technologies, and we have begun to incorporate innovative features into CBT2go, including location-based data and personalized predictive modeling, that can potentially lead to transformative mobile interventions. We propose a research study with the overarching aims of evaluating the effectiveness of CBT2go, gathering necessary data to refine its innovative features, and examining its costs, facilitators, and barriers to implementation in a public mental health system. We propose a randomized controlled trial with three arms: 1) CBT2go, 2) an ecological momentary assessment only condition to control for self-monitoring and device contact, and 3) standard care. A total of 255 participants with either BD or SZ will be recruited from a large public mental health system that has minimal access to CBT. Participants will be assessed at baseline, 6 weeks (mid-treatment), 12 weeks (post-treatment) and 24 weeks (follow-up). The primary outcome of the study will be clinician rated global psychopathology, and secondary outcomes will include medication adherence, social functioning, and mental health service utilization. Recognizing that not all participants will benefit, we propose to examine differential effectiveness in sub-groups. We will also examine mechanisms of change to inform mobile intervention design, focusing on the impact of CBT2go on cognitive insight and dysfunctional attitudes, which are two mediators of change in traditionally delivered CBT. Drawing from experience in implementation research, we will employ a mixed methods approach to assessing the facilitators, barriers, and costs of adoption of CBT2go from perspectives of consumers, technology experts, administrators and front-line clinicians. This study will lay the groundwork for CBT2go to be adapted and implemented with high fidelity in healthcare settings.
Evidence from experimental animals provides strong support for the concept that caloric restriction (CR) increases resistance to multiple forms of stress. CR decreases plasma levels of growth factors, e.g. insulin-like growth factor-I (IGF-I), thereby diverting energy from growth to maintenance. Accordingly, the currently available information suggests that short-term fasting protects normal cells against the perils of (high dose) chemotherapy. In contrast, cancer cells are not (or less) protected as a result of their self-sufficiency in growth signals. This phenomenon is termed Differential Stress Resistance (DSR). DSR reduces the severity of side-effects caused by the toxicity of chemotherapy, without interfering with its effect on reduction of tumour volume or tumour markers. A recent report, sketching a case series of 10 cancer patients, suggests that short term fasting protects against the side effects of chemotherapy in humans. Indeed, the majority of patients preferred fasting over feeding in preparation of their therapy. This study aims to further evaluate the impact of fasting on tolerance to chemotherapy in humans.
Impaired Liver Function

Do not use Haloette in women with liver disease such as acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal and CHC causation has been excluded [see Use in Specific Populations (8.6)]. Discontinue Haloette use if jaundice develops.

Liver Tumors 

Haloette is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with CHC use. An estimate of the attributable risk is 3.3 cases per 100,000 CHC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long term (>8 years) CHC users. However, the attributable risk of liver cancers in CHC users is less than one case per million users.
Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
The present invention relates to a novel production method of edible pharmaceutical spherical particle strains, which can effectively solve the problems of bacterial filament rupture, severe damage, easy infection and fruiting body deformity. The present invention has the technical scheme that plant seeds are used as base materials, soaked in water and the aqueous solution of carbon elements, taken out and placed in a bottle or a bag and sprayed with edible strains, and the bottle or the bag is sealed for culture. The present invention has the advantages of simple method and easy operation. Bacterial filaments enwind on the surfaces of shells, so disparity is good. During inoculation, the present invention has no fracture, no rupture, no infection and quick fungus growth, eliminates the erosion of other kinds of fungi and plant pollen, guarantees the purity and the security of the strains and has extensive exploitation and application prospect. The present invention can bring benefit to human beings.
All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to this group will begin with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for for the first 6 weeks of post-operative care. Standard rehabilitation will continue until discharge.
PURPOSE: A method of making a therapeutic for burn treatment by grinding heated abalone shell and then mixing with vegetable oil, phenoxyethanol, sodium hydroxide and Acticoat is provided. The therapeutic for burn treatment treats burns quickly without adverse side effects such as nausea, emesis, diarrhea, appetite loss, vertigo or the like and heals damaged skin. CONSTITUTION: Abalone shells are heated at 1,000 to 3,000deg.C in a wood vessel and then ground to a size of 1μm or less. Thereafter, the abalone shell powder is mixed with vegetable oil in a ratio of 3:2 and additionally added with phenoxyethanol, sodium hydroxide and Acticoat. The vegetable oil is selected from sesame oil, olive oil, sunflower seed oil, corn oil and palm oil. The powdery therapeutic for burn treatment is applied to the burned area three times per day and shortens the duration of therapy from 90 to 100 days to about 3 to 5 days using conventional therapeutics.
The present invention relates to a medicine for treating burns and scalds by water and fire and a preparation method thereof. The preparation method comprises the steps that a. fresh raw hen eggs are selected and washed, raw hen egg white of the fresh raw hen eggs is taken out for standby application; b. 95 to 98 wt% of raw hen egg white and 2 to 5 wt% of edible salt are put into a medical stirring device to be fully and uniformly stirred at normal temperature, and then the mixture is bottled and sealed. The conception of the present invention is novel, the present invention directly adopts raw hen egg white and edible salt to be prepared into the medicine for treating scalds, and the problems of the general medicines for treating scalds on the aspect of treatment are avoided. In addition, the medicine of the present invention has the action of rapidly relieving pain, resisting infection and repairing wounds of the skin, and can treat scalds by hot water, hot oil and hot steam, burns by fire and electricity and various kinds of trauma bleeding. The clinical use proves that the medicine has the advantages of obvious analgesic effect, obvious treatment effect, no toxic or side effect, convenient use, no uneven and rough scars after healing, and no bad pigments of carbon black, etc., and furthermore, the healing rate reaches 100%.
The present invention relates to a tooth whitening strip of material having a shape adapted to fit a user's teeth. Each user has four front teeth, two canine teeth and additional back teeth, such as molars. Each tooth has a front side, a tip, and a back side. The strip of material is of a shape so that the strip will substantially cover the front side of at least the user's front four teeth and two canine teeth. The front sides of additional teeth may be covered. The tooth whitening strip will then fold over the tips and onto the back side of one or more of the front four teeth. However, the strip of material will not cover the tips of the two canine teeth.      The strip of material may be of any shape that allows for the canines to protrude. Possible shapes include substantially trapezoidal with or without stair stepped sides or notches, and rectangular with notches, stair stepped sides, or recesses.
Potential participants will be recruited by email and phone. Survivors who wish to participate will complete an online consent form and then a series of short questionnaires to determine study eligibility. This data collection will take place in DatStat Connect, which is the online consenting and data collection tool utilized for the CCSS. Consented/enrolled SJLIFE participants will receive a link via email to complete surveys related to autonomic functioning and current medical concerns and asked to schedule delivery of a WHOOP® strap prior kit prior to scheduling a device setup session with a team member. The kit will include the WHOOP® strap, brief instructions for setup, and prepaid return mailing materials. The WHOOP® strap will be shipped to the participant and each participant will complete a training session and app installation, if needed, and instructions regarding during of wear (two weeks)
Women with normal pregnancies. One blood sample in gestation week 25+0 to 37 matched as controls for PLC and PPROM cases.
The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
A method for treating paroxysmal vegetative insufficiency in the children comprises the use of the sedative drugs. Beforehand, the patients are examined with the aim of detecting cerebrosthenic syndrome. The patients are tested psychologically. Electroencephalography, cardiointervalography, rheoencephalography and Dopplerography of the neck-and-head vessels are performed. When the alterations of the psychological status and brain functions are revealed, Tenoten (dosage form for children) is provided at a dose of one tablet thrice a day. When the alterations in vegetative reactivity are evident, Homviotesin in a complex with Homvionervin are used at a dose of one tablet thrice a day. When cerebrosthenic syndrome is present with the impaired cerebral hemodynamics, Homvionervin is provided at a dose of one tablet thrice a day. The duration of the course of treatment is two months.